Cablevision’s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research.

Bookmark and Share

Research Awards Listing

Research follows dollars, and The Lustgarten Foundation believes that increasing funds for pancreatic cancer research will translate into enhanced patient care, and ultimately, a cure.

The Foundation provides the best and brightest minds with the resources and flexibility to pursue science of the highest quality. To date, we have committed more than $22 million for the study of pancreatic cancer research. What began as a small but dedicated community of pancreatic cancer researchers is now a critical mass of investigators with shared interest in the disease.

Listing By Area

Biology & Genetics

Aston University, United Kingdom
Michael J. Tisdale, DSc., Ph.D.
Mechanism of Muscle Protein Catabolism in Cancer Cachexia

Beth Israel Deaconess Medical Center
Hava Avraham, Ph.D.
Studies of CHK Kinase in Pancreatic Cancer Cells

Cold Spring Harbor Laboratory
Robert Lucito, Ph.D.
Genomic Analysis of Pancreatic Cancer Using DNA Microarrays

Creighton University School of Medicine
Thomas Adrian, Ph.D.
LOX Inhibitors for Pancreatic Cancer Treatment and Prevention

Columbia University
Argiris Efstratiadis, M.D., Ph.D.
Development of a Mouse Model of Pancreatic Cancer

Columbia University, College of Physicians and Surgeons
Paul B. Fisher, Ph.D.
Exploiting Defects in Molecular Circuitry to Selectively Kill Pancreatic Cancer Cells

Dana-Farber Cancer Institute
Nabeel Bardeesy, Ph.D.
Preclinical Model System for Kras Directed Pancreatic Tumor Maintenance and Biomarker Identification

Dana-Farber Cancer Institute
Nabeel Bardeesy, Ph.D.
Pancreatic Cancer Models for The Identification of Biomarkers and Tumor Maintenance Programs

Dana-Farber Cancer Institute / Harvard Medical School
Lynda Chin, M.D.
Comprehensive View of Pancreatic Cancer Oncogenomics

Dartmouth College
Catherine Carrière, Ph.D.
Adult Pancreatic Progenitor Cells as Targets of Oncogenic Events

Georgetown University Medical Center
Anna Riegel, Ph.D.
The Role of the Nuclear Receptor Coactivator AIB1in the Early Preneoplastic Stages of Pancreatic Cancer

Johns Hopkins Medical Institutions
Nita Ahuja, M.D.
Aberrant Hypermethylation of CpG Island Promoters in Pancreatic Cancer: Constructing a Hypermethylome

Johns Hopkins Medical Institutions
James Eshleman, M.D., Ph.D.
Pancreatic Cancer Tumor Suppressor Gene Discovery using RNAi

Johns Hopkins Medical Institutions
Anirban Maitra, MBBS
Genetic Basis of Familial Pancreatic Cancer: A Novel Approach Using Whole Genome Conversion and High-Throughput Oligonucleotide Microarrays

Johns Hopkins Medical Institutions
Anirban Maitra, MBBS
Synergistic Targeting of the Apoptotic Machinery in Pancreatic Cancer

Johns Hopkins Medical Institutions
Joshua Mendell, M.D., Ph.D.
The Role of MicroRNAs in the Pathogenesis of Pancreatic Cancer

Johns Hopkins Medical Institutions
Joshua Mendell, M.D., Ph.D.
Ras-Regulated MicroRNAs in Pancreatic Cancer

Johns Hopkins Medical Institutions
Gloria Su, Ph.D.
Identification of Tissue-Specific Promoters for Ductal Epithelium of Pancreas Using SAGE Libraries

Johns Hopkins Medical Institutions
Bert Vogelstein, M.D.
Sequencing the Genome of Pancreatic Cancers

Johns Hopkins Medical Institutions
Bert Vogelstein, M.D.
Development of Novel Diagnostic Approaches for the Early Detection of Pancreatic Neoplasms

Massachusetts General Hospital
Sarah Thayer, M.D., Ph.D.
Shh Links Chronic Inflammatory Injury to Pancreatic Carcinogenesis

Massachusetts General Hospital / Harvard Medical School
Sarah Thayer, M.D., Ph.D.
To Characterize the Contribution of Sonic Hedgehog to Pancreatic Neoplasia

Mayo Clinic at Rochester
Raul Urrutia, M.D.
Role of Novel Sp1-like Proteins in the Transcriptional Silencing Carcinogen-activating Enzymes in Exocrine Pancreatic Cells

Meharry Medical College and Vanderbilt University
Ana M. Grau, M.D.
Role of Rhob in Tumorigenesis and Metastasis In Pancreatic Cancer

Mt. Sinai Hospital, Toronto / Samuel Lunenfeld Research Institute
Steven Gallinger, M.D.
A Novel Pancreatic Cancer Tumor Suppressor Candidate Gene

Northwestern University
Paul Grippo, Ph.D.
Dual Targeting of Mutant Kras And Muchin1 in Mice That Develop Human Like Panins

Purdue University
Stephen F. Konieczny, Ph.D.
Mist 1 Kras G12D Generated Pancreatic Cancer

Samuel Lunenfeld Research Institute
Steven Gallinger, M.D.
Characterization of Germline DNA Copy Number Variation in Familial Pancreas Cancer

Stanford University
Anson W. Lowe, M.D.
Characterizing the Gene-expression Profile of Human Pancreatic Cancers

Stanford University School of Medicine
Jonathan Pollack, M.D., Ph.D.
Locating Novel Pancreatic Cancer Genes with DNA Microarrays

Technical University of Munich
Roland Schmid, M.D.
Jens T. Svieke, M.D.
The Role of Notch Signaling in Pancreatic Cancer Development

University of California at Davis Cancer Center
Richard Bold, M.D.
Anti-apoptotic Signaling through the AKT Kinase in Pancreatic Cancer

University of California at San Francisco Cancer Center
Matthias Hebrok, Ph.D.
Embryonic Signaling Pathways in Pancreatic Cancer

University of Michigan
Craig Logsdon, Ph.D.
The Role of ATDC in Radioresistance of Pancreatic Adenocarcinoma

University of Michigan
Chandan Kumar, Ph.D.
Discovery of Recurrent Gene Fusions in Pancreatic Cancer Using High-Throughput Sequencing

University of North Carolina at Chapel Hill
Adrienne D. Cox, Ph.D.
Functional Consequences of Oncogenically Mutated Kras in Pancreatic Cancer

University of Texas M.D. Anderson Cancer Center
Lee Ellis, M.D.
Role of Neuropilin-1 in Pancreatic Cancer Growth and Angiogenesis AP-1 and Ras Signaling in Pancreatic Cancer Cells

University of Texas M.D. Anderson Cancer Center
Shrikanth A. G. Reddy, Ph.D.
AP-1 and Ras Signaling in Pancreatic Cancer Cells

University of Texas M.D. Anderson Cancer Center
Keping Xie, M.D., Ph.D.
Control of Pancreatic Cancer Metastasis by Modulating Tumor-associated Nitric Oxide Production

University of Texas at San Antonio
James Freeman, Ph.D.
TGF-B Type II Receptor Gene as a Target for the Antitumor Effect of Farnesyltransferace Inhibitors in Pancreatic Cancer

Top of Page

Early Detection & Screening

Canary Foundation
Brad Nelson, Ph.D.
The Pancreatic Cancer Biomarker Initiative

Dana-Farber Cancer Institute
James DeCaprio, M.D.
The Pancreatic Cancer Biomarker Initiative

Johns Hopkins Medical Institutions
Marcia Canto, M.D.
Screening for Early Pancreatic Neoplasia: a Multi-Center Study

Johns Hopkins Medical Institutions
Michael Goggins, M.D.
Detect Early Symptomless Pancreatic Cancer

Johns Hopkins Medical Institutions
Michael G. Goggins, M.D.
Proteomic Profiles of Pancreatic Cancer

Johns Hopkins Medical Institutions
Michael Goggins, M.D.
Proteomic Profiles of Pancreatic Juice for the Early Detection of Pancreatic Cancer

Johns Hopkins Medical Institutions
Michael Goggins, M.D.
Novel Strategies and Technologies for Identifying Familial Pancreatic Cancer Genes

Massachusetts General Hospital
Kimberly Kelly, Ph.D.
Development of Molecular Imaging Agents for Early Detection of Pancreatic Cancer

Massachusetts General Hospital
Kimberly A. Kelly, Ph.D.
Plectin-1 As A Biomarker for the Early Detection of Pancreatic Ductal Adenocarcinoma

Mayo Clinic College of Medicine
Janet Olsen, Ph.D.
Identification of Early Stage Pancreatic Cancer Biomarkers using LC-Dual ESI-FT-ICR Mass Spectrometry

Mayo Clinic at Rochester
Suresh T. Chari, M.D.
Serum Proteomics of Pancreatic Cancer- Induced Diabetes

Mayo Clinic
Amy Tang, Ph.D.
SIAH: A Novel Biomarker of Pancreatic Cancer Progression and Therapeutic Implications

Memorial Sloan-Kettering Cancer Center
Gary K. Schwartz, M.D.
Clinical Development of Flavorpiridol for Patients With Locally Advanced and Metastatic Pancreatic Cancer

Ohio State University
Thomas Schmittgen, Ph.D.
MicroRNA Profiling in Serum of Pancreatic Adenocarcinoma Patients
* Supported by a generous donation from Michael Rolfe Pancreatic Cancer Foundation

University of California at San Francisco
James D. Marks, M.D., Ph.D.
The Pancreatic Cancer Biomarker Initiative

University of Michigan Medical Center
Diane M. Simeone, M.D.
Development and Validation of Novel Biomarkers for Early Pancreatic Cancer Detection

University of Michigan Medical Center
Diane Simeone, M.D.
Pancreatic Cancer Stem Cells

Van Andel Research Institute
Brian B. Cao, M.D.
The Pancreatic Cancer Biomarker Initiative

Top of Page

Etiology & Epidemiology

Dana-Farber Cancer Institute
Charles Fuchs, M.D., M.P.H.
Prospective Study of Pancreatic Cancer Pathogenesis

Harvard School of Public Health
Eric J. Duell, Ph.D.
Gene-Environment Interactions in Pancreatic Adenocarcinoma

Johns Hopkins Medical Institutions
Constance Griffin, M.D.
Chromosome Analysis in Patients with Familial Pancreatic Cancer

Johns Hopkins Medical Institutions
Christine Iacobuzio-Donahue, M.D., Ph.D.
Towards a Comprehensive Understanding of Pancreas Cancer Through Gene Expression Profiling

Johns Hopkins Medical Institutions
Allison Klein, Ph.D.
Identification of Pancreatic Cancer Susceptibility Genes

Mayo Clinic College of Medicine
Fergus J. Couch, Ph.D.
Genetic Epidemiology of Novel Pancreatic Cancer Susceptibility Genes

Mayo Clinic at Rochester
Gloria M. Peterson, Ph.D.
Genetic Epidemiology of Pancreatic Cancer

University of Pittsburgh
David C. Whitcomb, M.D., Ph.D.
Identify Genes Which are Only Expressed in Pancreatic Cancer Cells [check this]

Top of Page

Scientific Modeling Systems

Columbia University
Timothy Wang, M.D.
Development of An Inflammation-Based Pancreatic Cancer Model and Exploration of the Origins of Pancreatic Cancer
Supported by a generous donation from The Lefkofsky Family Foundation

Johns Hopkins Medical Institutions
Steven D. Leach, M.D.
Notch Signaling in Pancreatic Cancer Precursors

Johns Hopkins Medical Institutions
Steven Leach, M.D.
Zebrafish Model of Early Pancreatic Cancer

Johns Hopkins Medical Institutions
Gloria Su, Ph.D.
Mouse Models for Human Pancreatic Cancer

Salk Institute for Biological Studies
Inder M. Verma, Ph.D.
A Novel Mouse Model of Pancreatic Cancer Using Lentiviral Vectors

State University of New York at Stony Brook
Dafna Bar-Sagi, Ph.D.
Analysis of Pancreatic Ductal Adenocarcinoma Progression in a Mouse Model of Hereditary Pancreatitis

University of California at San Francisco Cancer Center
Martin McMahon, Ph.D.
A Systematic, Genome-Wide Analysis of Gene Copy Number Alteration in Pancreatic Cancer Cells by Array CGH

University of Nebraska Medical Center/Eppley Cancer Research Institute
Michel Ouellette, Ph.D.
In-Vitro Models of Pancreatic Cancer Development

University of Pittsburgh Cancer Institute
Katherine Pogue-Geile, Ph.D.
Functional Identification of Pancreatic Tumor Suppressor Genes

University of Utah
Lewis Charles Murtaugh, Ph.D.
Interdependence of Notch and Kras Signaling in Pancreatic Tumorigenesis

Top of Page

Therapy

Aston University, United Kingdom
Michael Tisdale, Dsc., Ph.D.
Cloning and Expression of a Muscle Receptor for a Cancer Cachectic Factor

Cambridge Research Institute
David Tuveson, M.D., Ph.D.
Novel Anti-K-ras Strategies in Ductal Pancreatic Cancer

Dana-Farber Cancer Institute
David Frank, M.D., Ph.D.
Inhibition of STAT3 in the Targeted Therapy of Pancreatic Cancer

Dana-Farber Cancer Institute / Harvard Medical School
Muneesh Tewari, M.D., Ph.D.
A Synthetic Lethal Screen to Discover Tumor-Selective Drug Targets in Pancreatic Cancer

Duke University Medical Center
Douglas Tyler, M.D.
Immunotherapy of Pancreatic Cancer Using Dendritic Cells Pulsed with Antigen in the Form of Amplified Total Tumor R

Fred Hutchinson Cancer Research Center
Sunil Hingorani, M.D., Ph.D.
Oncogenic Kras as a Therapeutic Target for Pancreas Cancer

Johns Hopkins Medical Institutions
Elizabeth Jaffee, M.D.
Functional Genomic Approach to Identify Genes That are Pancreatic Cancer Immune Target

Johns Hopkins Medical Institutions
Elizabeth Jaffee, M.D.
A Phase II Study of an Allogeneic Gm-CSF Secreting Pancreatic Tumor Vaccine

Johns Hopkins Medical Institutions
Steven D. Leach, M.D.
High-Throughput, In-Vivo Screening for Novel Pancreatic Cancer Drugs Using the Zebrafish System

Johns Hopkins Medical Institutions
Anirban Maitra, MBBS
Hedgehog Inhibitors of Pancreatic Cancer

Johns Hopkins Medical Institutions
Anirban Maitra, MBBS
Targeting the Herpes Virus Entry Mediator (HVEM) As A Novel Therapeutic Strategy in Pancreatic Cancer

Massachusetts General Hospital
Jeffrey Settleman, Ph.D.
Identification and Validation of Novel Therapeutics for Kras-Mutant Pancreatic Cancer

Memorial Sloan-Kettering Cancer Center
Yuman Fong, M.D.
Synergy of Herpes Viruses with Chemotherapy or Immunotherapy in the Treatment of Pancreatic Cancer

Memorial Sloan-Kettering Cancer Center
Richard N. Kolesnick, M.D.
Development of KSR Phosphorothioate Antisense Oligonucleotides in the Treatment of Human Pancreatic Cancer

New York University School of Medicine
Daniel Meruelo, Ph.D.
Imaging-Assisted Design of Viral Vectors to Eradicate Metastatic Pancreatic Cancer

NYU School of Medicine
Steven Hofstetter, M.D.
Evaluation of Pancreatic Cancer Growth and Metastasis in Plasminogen Activator Deficient Mice

Stanford University
Albert Koong, M.D., Ph.D.
Selective Modulators of Protein Kinase C Activity as a Novel Class of Hypoxia Cell Cytotoxins in Human Pancreatic Cancer

Stanford University School of Medicine
Jonathan R. Pollack, M.D., Ph.D.
Locating Novel Pancreatic Cancer Genes With DNA Microarrays

SUNY Downstate Medical Center
Josef Michl, M.D.
Matthew R. Pincus, M.D., Ph.D.
Novel Methods in the Diagnosis and Treatment of Pancreatic Cancer

University of Alabama at Birmingham
David T. Curiel, M.D.
Pancreatic Carcinoma Specific Replicative Adenoviral Agent

University of Alabama at Birmingham
Pierre L. Triozzi, M.D.
ErbB Receptor Immunotherapy

University of California at San Francisco Cancer Center
Allan Balmain, Ph.D.
Therapeutic Approaches to Pancreatic Cancer Based on Kras Isoform 4A Expression in Stem Cells

University of California at San Francisco Cancer Center
Martin McMahon, Ph.D.
Targeting Kinases to Overcome Gemcitabine Resistance in Pancreatic Carcinoma

University of California at San Francisco Cancer Center
Margaret Tempero, M.D.
Optimizing Therapy for Pancreatic Adenocarcinoma with TALL-104 Cells

University of Pittsburgh Cancer Institute
Ramesh K. Ramanathan, M.D.
Co-Principal Investigator: Olivera Finn, Ph.D.
Phase I/II Study of a MUC-1 Pulsed Dendritic Cell Vaccine In Resected Pancreatic and Biliary Cancers

University of Texas M.D. Anderson Cancer Center
George Halder, Ph.D.
A Novel Genetic System to Identify Ideal Cancer Drug Targets in Pancreatic Cancer

University of Texas M.D. Anderson Cancer Center
David McConkey, M.D., Ph.D.
A Novel Therapy for Advanced Pancreatic Cancer

University of Washington
Teresa Brentnall, M.D.
Discovery of a Familial Pancreatic Cancer Gene 

Top of Page

2009 Annual Report 

Read about our 100% commitment in the fight against pancreatic cancer.

Stimulating Research

Lustgarten Foundation grantees have secured more than $80 million in additional research awards from leading institutions.

Join Now

The Lustgarten Foundation
1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303
©2009 Lustgarten Foundation